Activators of EF-CAB9 directly or indirectly influence its functional activity by modulating intracellular signaling pathways that converge on the protein's ability to bind calcium. Several small molecule compounds exert their effects by increasing the intracellular concentration of cyclic AMP (cAMP), a second messenger that activates protein kinase A (PKA). Upon activation, PKA can phosphorylate EF-CAB9, thereby enhancing its calcium sensitivity and functional activity. Other activators function by directly elevating intracellular calcium levels, either through agonism at calcium channels, thereby permitting more calcium influx, or by acting as calcium ionophores that shuttle calcium ions across the cell membrane. The increase in intracellular calcium can augment the ability of EF-CAB9 to bind calcium, which is central to its biological role. Additionally, certain compounds can influence calcium signaling indirectly by inhibiting the degradation of cAMP or by modulating G-protein coupled receptor pathways, which leads to increased intracellular calcium levels that could subsequently activate EF-CAB9.
Furthermore, activators such as dihydropyridines and other calcium channel modulators exert their effects by altering the dynamics of calcium entry into the cell. While some may block specific types of calcium channels, resulting in a compensatory increase in intracellular calcium release from intracellular stores, others may directly augment the calcium flow through ion channels. This modulation of calcium homeostasis is critical, as it ensures that EF-CAB9 has an adequate supply of calcium ions necessary for its activation and subsequent physiological functions. In addition to these mechanisms, other activators work by mimicking the structure and function of cAMP, thus directly activating PKA and promoting the phosphorylation of EF-CAB9.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Activates adenylyl cyclase increasing cAMP levels, which can enhance the calcium sensitivity of EF-CAB9 by phosphorylation via PKA. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
Activates protein kinase C (PKC) which could phosphorylate EF-CAB9, modulating its calcium-binding properties and enhancing its function. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $27.00 $37.00 | 5 | |
Beta-adrenergic agonist that raises intracellular cAMP, potentially leading to EF-CAB9 activation through PKA-mediated phosphorylation. | ||||||
(±)-Bay K 8644 | 71145-03-4 | sc-203324 sc-203324A sc-203324B | 1 mg 5 mg 50 mg | $82.00 $192.00 $801.00 | ||
L-type calcium channel agonist that increases intracellular calcium, potentially enhancing EF-CAB9 activation due to its calcium-binding domain. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
Ionophore that increases intracellular calcium concentration, directly augmenting EF-CAB9's calcium-dependent activity. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $97.00 $224.00 | 30 | |
cAMP analog that activates PKA, subsequently leading to phosphorylation and activation of EF-CAB9. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Calcium ionophore that raises intracellular calcium levels, potentially activating EF-CAB9 by increasing its calcium binding. | ||||||
Nicotinic Acid | 59-67-6 | sc-205768 sc-205768A | 250 g 500 g | $61.00 $122.00 | 1 | |
Raises intracellular calcium levels through the activation of G-protein coupled receptors, potentially enhancing EF-CAB9 activity. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $90.00 $350.00 | 16 | |
Phosphodiesterase-3 inhibitor that increases cAMP, potentially leading to activation of EF-CAB9 via PKA-mediated phosphorylation. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
Phosphodiesterase inhibitor that prevents cAMP degradation, potentially leading to PKA activation and phosphorylation of EF-CAB9. | ||||||